The Nab-PTX formulation eliminates the impact of Cremophor-EL on PTX pharmacokinetics and utilizes the endogenous albumin transport mechanisms to concentrate Nab-PTX in the tumor, leading to improved anti-cancer efficacy (Stinchcombe, 2007; Kinoshita et al., 2014; Carlier et al., 2018). This evidence concerns the gene ALB and cancer.